Mazumder Rupa, Chaudhuri Sharmila Ray, Mazumder Avijit
Department of Pharmaceutical Sciences, Birla Institute of Technology, Mesra, Ranchi 835 215.
Indian J Exp Biol. 2002 Jul;40(7):828-30.
The antipsychotic drug, prochlorperazine (Pcp), was tested for its antimicrobial efficacy against 103 strains belonging to both gram positive and gram negative bacteria. The drug was found to possess maximum activity against Staphylococcus aureus, Vibrio cholerae and Shigella spp. Pcp was moderately active against E. coli but most of the strains belonging to Bacillus spp, Klebsiella spp, Salmonella spp and Lactobacillus spp were found to be resistant to this drug. The drug was tested for its mode of antibacterial activity against Shigella dysenteriae 1 and it was found to be bacteriostatic in action. In in vivo studies, Pcp offered significant protection to Swiss albino mice at concentrations of 0.75 micro g/g (P < 0.01) and 1.5 microg/g (P < 0.001) body weight when challenged with 50 median lethal dose of Salmonella typhimurium NCTC 74. Thus the result depicts that prochlorperazine may emerge as a strong antimicrobial drug to replace the conventional antibiotics and to overcome the problem of drug resistance.
对精神抑制药物氯丙嗪(Pcp)针对103株革兰氏阳性和革兰氏阴性细菌的抗菌效力进行了测试。发现该药物对金黄色葡萄球菌、霍乱弧菌和志贺氏菌属具有最大活性。氯丙嗪对大肠杆菌有中等活性,但发现大多数芽孢杆菌属、克雷伯氏菌属、沙门氏菌属和乳酸杆菌属的菌株对该药物耐药。测试了该药物对痢疾志贺氏菌1型的抗菌作用模式,发现其作用为抑菌。在体内研究中,当用50个半数致死剂量的鼠伤寒沙门氏菌NCTC 74攻击时,氯丙嗪以0.75微克/克(P < 0.01)和1.5微克/克(P < 0.001)的体重浓度为瑞士白化小鼠提供了显著保护。因此,结果表明氯丙嗪可能成为一种强大的抗菌药物,以取代传统抗生素并克服耐药性问题。